Heart failure and iron deficiency anemia in Italy: Results from CARMES-1 registry

Future Cardiology

Volumn 9, Issue 3, 2013, Pages 437-444

  Caira, Carmen ^a   Ansalone, Gerardo ^b   Mancone, Massimo ^a   Canali, Emanuele ^a   Pagliaro, Michela ^a   Fratarcangeli, Lara ^a   Aznaran, Carlos Alberto Centurion ^a   Gatto, Maria Chiara ^a   Pietro, Riccardo Di ^a   Fedele, Francesco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Madre Giuseppina Vannini Hospital   (Italy)

Author keywords

anemia; current iron deficiency treatment strategies; heart failure; hospital readmission; iron deficiency; mortality

Indexed keywords

ANTIANEMIC AGENT; FERRIC GLUCONATE; FERRITIN; FERROUS SULFATE; FOLIC ACID; HEMOGLOBIN; IRON; TRANSFERRIN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART FAILURE; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; IRON DEFICIENCY ANEMIA; IRON THERAPY; ITALY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREVALENCE; PRIORITY JOURNAL;

ADULT; ANEMIA, IRON-DEFICIENCY; FEMALE; HEART FAILURE; HOSPITAL MORTALITY; HUMANS; INPATIENTS; ITALY; LENGTH OF STAY; MALE; MIDDLE AGED; PATIENT READMISSION; PREVALENCE; REGISTRIES; RETROSPECTIVE STUDIES;

EID: 84877847751     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.13.12     Document Type: Article

References (23)

1. Gheorghiade M, Zannad F, Sopko G et al. Acute heart failure syndromes: current state and framework for future research. Circulation 112, 3958-3968 (2005).
2. Adams FK, Fonarow GC, Emerman CL et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 149, 209-216 (2005).
3. Cleland JG, Swedeberg K, Follath F et al. The Euroheart Failure Survey programme: a survey on the quality of care among patients with heart failure in Europe: part I patients characteristics and diagnosis. Eur. Heart J. 24, 442-463 (2003).
4. Di Lenarda A, Scherillo M, Maggioni AP et al. Current presentation and management of heart failure in cardiology and internal medicine hospital units: a tale of two worlds-the TEMISTOCLE study. Am. Heart J. 146(4), 1-10 (2003).
5. Fabbri G, Gorini M, Maggioni AP, Cacciatore G, Di Lenarda A. IN-CHF: il registro italiano dello scompenso cardiaco. Dieci ani di esperienza. G. Ital. Cardiol. 7(10), 689-694 (2006).
6. Tavazzi L, Maggioni AP, Lucci D et al. Nationwide survey on acute heart failure in cardiology ward services in Italy. Eur Heart J. 27, 1207-1215 (2006).
7. Tang YD, Katz S. Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options. Circulation 113 (20), 2454-2461 (2006).
8. Silverberg D, Wexler D, Blum M et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J. Am. Coll. Cardiol. 35(7), 1737-1744 (2000).
9. Nanas JN, Matsouka C, Karageorgopoulos D et al. Etiology of anemia in patients with advanced heart failure. JAAC 48, 2485-2489 (2006).
10. Anand I, McMurray JJ, Whitmore J et al. Anemia and its relationship to clinical outcome in heart failure. Circulation 110, 149-154 (2004).
11. Toblli JE, Lombraña A, Duarte P, Di Gennaro F. Intravenous iron reduces NT proBNP in anemic patients with chronic heart failure and renal insufficiency. JACC 50, 1657-1665 (2007).
12. Okonko DO, Grzeslo A, Witkowski T et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and non anemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF a randomized controlled observer-blinded trial. JACC 51, 103-112 (2008).
13. Anker S, Colet J,Filippatos G et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N. Engl. J. Med. 361, 1-13 (2009).
14. Ponikowski P, Macdougall I, Colet JC et al. The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study. Circulation 22, A17341 (2010).
15. Bailie GR, Mason NA, Valaoras TG. Safety and tolerability of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Hemodila. Int. 14(1), 47-54 (2010).
16. Groenveld HF, Januzzi JL, Damman K et al. Anemia and mortality in heart failure patients: a systematic review and meta-analysis. JACC 53, 818-827 (2008).
17. Okonko O, Grzeslo A, Witkowski T et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J. Am. Coll. Cardiol. 51, 2 (2008).
18. Jankowska EA, Rozentryt P, Witkowska A et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J. 31(15), 1872-1880 (2010).
19. McMurray JJ, Adamopoulos S, Anker S. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 33, 1787-1847 (2012).
20. van Veldhuissen DJ, Dikstein K, Cohen Solal A et al. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur. Heart J. 28, 2208-2216 (2007).
21. Gahli JK, Anand IS, Abraham WT et al. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation 117, 526-635 (2008).
22. Parissis JT, Kourea K, Panou F et al. Effects of darbopietina alpha on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic cardiomyopathy. Am. Heart J. 155(4), 751.e1-751.e7 (2008).
23. Kourea K, Parissis JT, Farmakis D et al. Effects of darbepoetin-alpha on quality of life and emotional stress in anemic patients with chronic heart failure. Eur. J. Cardiovasc. Prev. Rehabil. 15, 365-369 (2008).